Rebuking FDA, NIH experts say 'no data' support plasma as a COVID-19 treatment Roche to launch 40M rapid coronavirus antigen tests per month, starting in Europe COVID-19 often undetected in workers on hospital frontlines, CDC says CDC sets its sights on November COVID-19 vaccine deliveries: report Providence to spend $50M to reduce health disparities, starting with COVID-19 care gaps Trust pharma for coronavirus news? Most people say yes, but more Democrats than Republicans: poll Healthcare roundup: Google, Apple integrate contact tracing tech into Android, iOS Biopharma roundup: Catalent, on the hook for AZ, J&J shots, invests $50M in Indiana plant; vaccine trials could wrap early on strong results: Fauci Catalent pumps $50M into Indiana fill-finish capacity with COVID-19 vaccine contracts in hand HHS hands D.C. consultants $250M to 'inspire hope' with pandemic campaign Two-thirds of healthcare experts plot virtual trial use as a result of COVID-19: report Featured Story | By Eric Sagonowsky After the FDA's emergency use authorization for plasma late last month, NIH experts concluded that the therapy "should not be considered" standard of care for treating coronavirus patients. Why? There's "currently no data" that testifies to its efficacy and safety in COVID-19, the agency said. read more |
| |
|---|
|
Top Stories By Conor Hale Roche plans to make a rapid antigen test for the novel coronavirus widely available in Europe later this month, while also submitting it to FDA reviewers for an emergency authorization in the U.S. read more By Tina Reed More workers in hospitals may have been infected with COVID-19 than previously realized because their cases went undiagnosed, according to a new report from the Centers for Disease Control and Prevention. read more By Eric Sagonowsky With investigators recruiting participants for late-stage COVID-19 vaccine trials, officials are working behind the scenes at the federal, state and local levels to deliver the first doses by November 1, McClatchy reports. That timeline appears to be ahead of when the shots can definitively prove safety and efficacy. read more By Robert King Providence health system announced a new $50 million initiative aimed at narrowing racial disparities in healthcare, starting with those impacted by COVID-19 read more By Beth Snyder Bulik What’s the most trustworthy source when it comes to COVID-19 vaccine news? Your answer may depend on whether you’re a Republican or a Democrat. A new Harris Poll found that while members of both parties consider doctors, nurses and famous hospitals like the Mayo Clinic as the most trustworthy sources, the two groups diverge elsewhere. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner Catalent will build a third filling line at its Bloomington, Indiana, plant. Vaccine trials could end early if results are strong, Anthony Fauci said. The HHS tapped Fors Marsh Group to lead its COVID-19 messaging campaign. The U.K. endorsed hydrocortisone in COVID-19. Plus, Republicans and Democrats both trust pharmas working on vaccines, a poll found. read more By Kyle Blankenship With a suite of coronavirus vaccine hopefuls looking for manufacturing partners, major contract manufacturers are stepping in to help handle the load. One of those, New Jersey's Catalent, is now injecting some significant change into one of its U.S. plants to keep up with demand. read more By Beth Snyder Bulik HHS has picked a firm for its plum $250 million coronavirus campaign work: the Washington D.C. consultancy Fors Marsh Group. The company’s winning proposal is evidence-based and built on “principles of behavioral and social science," according to media reports. Its campaign partners will include large ad agency and media groups VMLY&R and iHeartMedia. read more By Ben Adams A new report by life science data analytics firm GlobalData has found that two-thirds of healthcare experts surveyed over the summer plan to use decentralized clinical trials. read more |
